CA3028175C - Methods of producing heterologous viral neuraminidase proteins in microalgae - Google Patents

Methods of producing heterologous viral neuraminidase proteins in microalgae Download PDF

Info

Publication number
CA3028175C
CA3028175C CA3028175A CA3028175A CA3028175C CA 3028175 C CA3028175 C CA 3028175C CA 3028175 A CA3028175 A CA 3028175A CA 3028175 A CA3028175 A CA 3028175A CA 3028175 C CA3028175 C CA 3028175C
Authority
CA
Canada
Prior art keywords
protein
schizochytrium
viral
seq
microalgal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3028175A
Other languages
English (en)
French (fr)
Other versions
CA3028175A1 (en
Inventor
Kirk Emil Apt
Anne-Cecile V. Bayne
James Casey Lippmeier
Ross Eric Zirkle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Vaccine Technologies SAS
Original Assignee
Sanofi Vaccine Technologies SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Vaccine Technologies SAS filed Critical Sanofi Vaccine Technologies SAS
Priority to CA3153553A priority Critical patent/CA3153553A1/en
Publication of CA3028175A1 publication Critical patent/CA3028175A1/en
Application granted granted Critical
Publication of CA3028175C publication Critical patent/CA3028175C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/02Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/145Orthomyxoviridae, e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/12Unicellular algae; Culture media therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5258Virus-like particles
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16123Virus like particles [VLP]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151Methods of production or purification of viral material
    • C12N2760/16152Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01018Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Botany (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3028175A 2009-12-28 2010-12-28 Methods of producing heterologous viral neuraminidase proteins in microalgae Active CA3028175C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3153553A CA3153553A1 (en) 2009-12-28 2010-12-28 Methods of producing heterologous proteins comprising membrane domains in microalgal extracellular bodies

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US29044109P 2009-12-28 2009-12-28
US29046909P 2009-12-28 2009-12-28
US61/290,441 2009-12-28
US61/290,469 2009-12-28
US41335310P 2010-11-12 2010-11-12
US61/413,353 2010-11-12
CA2785971A CA2785971C (en) 2009-12-28 2010-12-28 Production of heterologous polypeptides in microalgae, microalgal extracellular bodies, compositions, and methods of making and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2785971A Division CA2785971C (en) 2009-12-28 2010-12-28 Production of heterologous polypeptides in microalgae, microalgal extracellular bodies, compositions, and methods of making and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3153553A Division CA3153553A1 (en) 2009-12-28 2010-12-28 Methods of producing heterologous proteins comprising membrane domains in microalgal extracellular bodies

Publications (2)

Publication Number Publication Date
CA3028175A1 CA3028175A1 (en) 2011-07-28
CA3028175C true CA3028175C (en) 2022-05-24

Family

ID=44307127

Family Applications (3)

Application Number Title Priority Date Filing Date
CA3028175A Active CA3028175C (en) 2009-12-28 2010-12-28 Methods of producing heterologous viral neuraminidase proteins in microalgae
CA2785971A Active CA2785971C (en) 2009-12-28 2010-12-28 Production of heterologous polypeptides in microalgae, microalgal extracellular bodies, compositions, and methods of making and uses thereof
CA3153553A Pending CA3153553A1 (en) 2009-12-28 2010-12-28 Methods of producing heterologous proteins comprising membrane domains in microalgal extracellular bodies

Family Applications After (2)

Application Number Title Priority Date Filing Date
CA2785971A Active CA2785971C (en) 2009-12-28 2010-12-28 Production of heterologous polypeptides in microalgae, microalgal extracellular bodies, compositions, and methods of making and uses thereof
CA3153553A Pending CA3153553A1 (en) 2009-12-28 2010-12-28 Methods of producing heterologous proteins comprising membrane domains in microalgal extracellular bodies

Country Status (9)

Country Link
US (3) US20110189228A1 (show.php)
EP (3) EP2519635B1 (show.php)
JP (5) JP6339548B2 (show.php)
CN (2) CN107746869A (show.php)
AU (4) AU2010343095B2 (show.php)
CA (3) CA3028175C (show.php)
EA (1) EA022841B1 (show.php)
IN (1) IN2012DN06277A (show.php)
WO (1) WO2011090731A1 (show.php)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI350854B (en) 2001-04-16 2011-10-21 Martek Biosciences Corp Product and process for transformation of thraustochytriales microorganisms
KR101786121B1 (ko) 2009-03-16 2017-10-16 디에스엠 아이피 어셋츠 비.브이. 라비린툴로바이코타문 미생물에서의 단백질 생산
US9012197B2 (en) * 2009-12-28 2015-04-21 Merial, Inc. Production of hemagglutinin-neuraminidase protein in microalgae
EP3213766A1 (en) * 2009-12-28 2017-09-06 Merial Ltd. Recombinant ndv antigen and uses thereof
EP2444495A1 (en) * 2010-10-20 2012-04-25 Algenics Secretion of recombinant polypeptides in the extracellular medium of diatoms
CN103649313B (zh) * 2011-03-07 2017-10-24 Dsm营养产品股份公司 工程化破囊壶菌属微生物
BR112014004188A2 (pt) * 2011-08-24 2017-03-21 Novozymes Inc método para obter transformantes positivos de uma célula hospedeira fúngica filamentosa, célula hospedeira fúngica filamentosa, método para produzir múltiplos polipeptídeos recombinantes, e, construto em tandem
CA2879680A1 (en) 2012-07-24 2014-01-30 Bp Corporation North America Inc. Xylose isomerases and their uses
WO2014045191A2 (en) * 2012-09-18 2014-03-27 Myko Tech Private Limited Extracellular polysaccharides from labyrinthulomycetes with broad-spectrum antiviral activities
CN106793799B (zh) 2014-10-02 2021-05-14 赢创运营有限公司 用于养殖动物的方法
CN106793798A (zh) 2014-10-02 2017-05-31 赢创德固赛有限公司 具有高抗磨损性和高水稳定性的含pufa的饲料
EP3200606B1 (de) * 2014-10-02 2021-03-31 Evonik Operations GmbH Verfahren zur herstellung eines pufas enthaltenden futtermittels durch extrusion einer pufas enthaltenden biomasse des typs labyrinthulomycetes
CN107075540A (zh) 2014-10-02 2017-08-18 赢创德固赛有限公司 用于制备具有高细胞稳定性的含pufa生物质的方法
AU2016226418B2 (en) 2015-03-02 2022-05-26 Synthetic Genomics, Inc. Regulatory elements from labyrinthulomycetes microorganisms
JP6977231B2 (ja) 2015-07-13 2021-12-08 マラ リニューアブルズ コーポレーション C5有機炭素の微生物による代謝の増強
FR3038913B1 (fr) * 2015-07-17 2020-05-01 Fermentalg Biomasse de thraustochytrides, procede de culture et utilisations
WO2018049284A1 (en) * 2016-09-09 2018-03-15 Cornell University Delivery of nucleic acids, proteins and small molecules in vitreous vesicular bodies
US10633454B2 (en) 2016-11-01 2020-04-28 Conagen Inc. Expression of modified glycoproteins and glycopeptides
WO2018098001A1 (en) * 2016-11-27 2018-05-31 Triton Algae Innovations, Inc. Method of purification of recombinant osteopontin from microalgae
CN111954713A (zh) * 2018-03-05 2020-11-17 科纳根公司 用于产生具有低硫酸化的糖分子的生物体和方法
US20210243881A1 (en) 2018-06-27 2021-08-05 Sumitomo Electric Industries, Ltd. Original form body of flexible printed-wiring board, method of manufacturing flexible printed-wiring board, concentrated photovoltaic power generation module, and light emitting module
US11752175B2 (en) 2018-09-21 2023-09-12 Cornell University Compositions and methods for glaucoma
CN109161576B (zh) * 2018-09-26 2020-08-07 武汉中科光谷绿色生物技术有限公司 促进枯草芽孢杆菌发酵生产n-乙酰神经氨酸的方法
JP7637903B2 (ja) * 2019-11-21 2025-03-03 パナソニックIpマネジメント株式会社 改変シアノバクテリア、改変シアノバクテリアの製造方法、及び、タンパク質の製造方法
IT201900024580A1 (it) 2019-12-18 2021-06-18 Consiglio Nazionale Ricerche Vescicole extracellulari da microalghe
CN111363045B (zh) * 2020-02-18 2021-12-17 厦门大学 一种流感、hiv嵌合蛋白及嵌合病毒疫苗的制备方法
JP2021186420A (ja) * 2020-06-03 2021-12-13 株式会社三洋物産 遊技機
CN111621471B (zh) * 2020-06-12 2022-03-11 成都世联康健生物科技有限公司 一种软组织胞外囊泡的提取方法及应用
JP2022028997A (ja) * 2020-07-31 2022-02-17 株式会社三洋物産 遊技機
CN112452506A (zh) * 2020-11-06 2021-03-09 五原县沃丰生物科技有限责任公司 一种培养基粉末的生产方法
US11175293B1 (en) 2021-01-04 2021-11-16 University Of Utah Research Foundation Rapid assay for detection of SARS-CoV-2 antibodies
WO2022269557A1 (en) * 2021-06-24 2022-12-29 Reliance Industries Limited Recombinant algae and production of spider silk protein from the recombinant algae
CN113698451B (zh) * 2021-08-02 2023-04-11 广东海洋大学 一种微藻多肽及其制备方法和应用
MX2024005483A (es) 2021-11-05 2024-05-22 Sanofi Pasteur Inc Vacunas contra influenza multivalentes que comprenden hemaglutinina recombinante y neuraminidasa y metodos para usar las mismas.
IL312502A (en) 2021-11-05 2024-07-01 Sanofi Sa Hybrid multivalent influenza vaccines containing hemagglutinin and neuraminidase and methods of using them
US20230310571A1 (en) 2021-11-30 2023-10-05 Sanofi Pasteur Inc. Human metapneumovirus vaccines
WO2023232976A1 (en) * 2022-06-03 2023-12-07 Ags Therapeutics Sas Extracellular vesicles from genetically-modified microalgae containing endogenously-loaded cargo, their preparation, and uses
CN119604298A (zh) 2022-06-14 2025-03-11 亨仁资助研究组办公室 用于疗法的细胞外囊泡
CN115992052A (zh) * 2022-11-18 2023-04-21 暨南大学 一种微藻类外泌体、其制备方法和应用
JP7546136B1 (ja) 2023-12-27 2024-09-05 ロート製薬株式会社 微細藻類由来の細胞外小胞を含有する組成物

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4659669A (en) * 1981-03-02 1987-04-21 Regents Of The Univ. Of California Microbial expression of human influenza hemagglutinin proteins
US4537769A (en) * 1982-04-06 1985-08-27 American Cyanamid Company Stabilization of influenza virus vaccine
US4752473A (en) * 1984-10-12 1988-06-21 The Regents Of The University Of California Expression of glycosylated human influenza hemagglutinin proteins
US5340742A (en) 1988-09-07 1994-08-23 Omegatech Inc. Process for growing thraustochytrium and schizochytrium using non-chloride salts to produce a microfloral biomass having omega-3-highly unsaturated fatty acids
US5762939A (en) * 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
CA2180965C (en) * 1994-01-11 2010-05-11 Tom Maria Deroo Influenza vaccine
US5824309A (en) * 1995-12-05 1998-10-20 University Of Massachusetts Recombinant gas vesicles and uses thereof
US8003772B2 (en) * 1999-01-14 2011-08-23 Martek Biosciences Corporation Chimeric PUFA polyketide synthase systems and uses thereof
KR20000075076A (ko) * 1999-05-28 2000-12-15 최태진 형질전환된 미세조류를 이용하여 외래 단백질을 생산하는 방법
CN1196788C (zh) * 2000-06-23 2005-04-13 惠氏控股有限公司 野生型和嵌合流感病毒样颗粒(vlp)的装配
US7795002B2 (en) 2000-06-28 2010-09-14 Glycofi, Inc. Production of galactosylated glycoproteins in lower eukaryotes
US20060029604A1 (en) 2000-06-28 2006-02-09 Gerngross Tillman U Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform
MXPA03000105A (es) 2000-06-28 2004-09-13 Glycofi Inc Metodo para producir glicoproteinas modificadas.
US20060257399A1 (en) 2000-06-28 2006-11-16 Glycofi, Inc. Immunoglobulins comprising predominantly a Man5GIcNAc2 glycoform
US7625756B2 (en) 2000-06-28 2009-12-01 GycoFi, Inc. Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells
TWI350854B (en) * 2001-04-16 2011-10-21 Martek Biosciences Corp Product and process for transformation of thraustochytriales microorganisms
AU2007249124B2 (en) * 2001-04-16 2012-05-17 Dsm Ip Assets B.V. Product and process for transformation of thraustochytriales microorganisms
WO2003068933A2 (en) * 2002-02-14 2003-08-21 Novavax, Inc. Optimization of gene sequences of virus-like particles for expression in insect cells
JP2005538343A (ja) 2002-04-12 2005-12-15 イラリア・カプア ノイラミニダーゼをコードする精製サブフラグメント、組み換えノイラミニダーゼ、及び動物予防におけるその使用
WO2004042001A2 (en) * 2002-05-17 2004-05-21 Emory University Virus-like particles, methods of preparation, and immonogenic compositions
US7332299B2 (en) 2003-02-20 2008-02-19 Glycofi, Inc. Endomannosidases in the modification of glycoproteins in eukaryotes
WO2005047501A1 (en) * 2003-02-24 2005-05-26 Johns Hopkins University Molecular vaccines employing nucleic acid encoding anti-apoptotic proteins
DK1629004T3 (da) * 2003-06-05 2008-11-17 Wyeth Corp Immunogene sammensætninger indeholdende venezuelansk hesteencephalitisvirus-replikonvektorer og paramyxovirus-proteinantigener
EP2530147B1 (en) * 2004-05-25 2014-09-10 MedImmune, LLC Influenza hemagglutinin and neuraminidase variants
US8936930B2 (en) * 2004-08-05 2015-01-20 Ben-Gurion University Of The Negev Research And Development Authority Red microalgae expressing exogenous polypeptides and methods of generating and utilizing same
AU2005322960A1 (en) * 2005-01-06 2006-07-13 The Johns Hopkins University RNA interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by DNA and transfected dendritic cell vaccines
JP4796786B2 (ja) * 2005-04-28 2011-10-19 富士フイルム株式会社 ラビリンチュラ類を形質転換可能なベクター
JP4796787B2 (ja) * 2005-04-28 2011-10-19 富士フイルム株式会社 ラビリンチュラ類への遺伝子導入法
US9216212B2 (en) * 2005-08-05 2015-12-22 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
US20080008725A1 (en) * 2005-08-16 2008-01-10 Hawaii Biotech, Inc. Influenza recombinant subunit vaccine
CA2642644A1 (en) * 2006-02-16 2007-09-07 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services Antiviral agents and vaccines against influenza
EP2476432B1 (en) * 2006-03-07 2015-08-19 Vaxinnate Corporation Compositions that include hemagglutinin, methods of making and methods of use thereof
MX340759B (es) * 2006-03-15 2015-03-11 Dsm Ip Assets B V * Aceites de semillas vegetales que contienen ácidos grasos poli-insaturados.
WO2007130327A2 (en) * 2006-05-01 2007-11-15 Technovax, Inc. Influenza virus-like particle (vlp) compositions
US20100047266A1 (en) * 2006-07-27 2010-02-25 Ligocyte Pharmaceuticals, Inc. Chimeric virus-like particles
US20100330105A1 (en) * 2006-08-22 2010-12-30 John Hopkins University Anticancer Combination Therapies
CA2615372A1 (en) * 2007-07-13 2009-01-13 Marc-Andre D'aoust Influenza virus-like particles (vlps) comprising hemagglutinin
KR20100120157A (ko) * 2007-11-27 2010-11-12 메디카고 인코포레이티드 헤마글루티닌을 발현하는 트랜스제닉 식물에서 생산된 재조합 인플루엔자 바이러스-유사 입자(VLPs)
EP2090648A1 (en) * 2008-02-12 2009-08-19 Institut Francais de Recherche pour l'Exploitation de la Mere(Ifremer) Production of glycosylated polypeptides in microalgae
KR20090096890A (ko) * 2008-03-10 2009-09-15 전남대학교산학협력단 대장균에서 조류인플루엔자 바이러스의 뉴라미니다제 n1을발현하기 위한 벡터 및 방법, 이의 사용방법, 및뉴라미니다제 저해제
FR2928926B1 (fr) * 2008-03-18 2015-08-21 Centre Nat Rech Scient Polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leur utilisation pour la production de compositions immunogenes
CA2718529C (en) * 2008-03-19 2014-06-17 Hexion Specialty Chemicals, Inc. Modifier for concrete and cement formulations and methods of preparing the same
KR101786121B1 (ko) 2009-03-16 2017-10-16 디에스엠 아이피 어셋츠 비.브이. 라비린툴로바이코타문 미생물에서의 단백질 생산
US9012197B2 (en) * 2009-12-28 2015-04-21 Merial, Inc. Production of hemagglutinin-neuraminidase protein in microalgae
EP3213766A1 (en) * 2009-12-28 2017-09-06 Merial Ltd. Recombinant ndv antigen and uses thereof

Also Published As

Publication number Publication date
EP3505632B1 (en) 2022-08-03
AU2022203980A1 (en) 2022-06-30
CN102822343A (zh) 2012-12-12
JP6666950B2 (ja) 2020-03-18
AU2010343095B2 (en) 2017-01-05
AU2017202195A1 (en) 2017-04-20
EP4130273C0 (en) 2024-06-12
EA201290567A1 (ru) 2013-02-28
EA022841B1 (ru) 2016-03-31
JP2018121660A (ja) 2018-08-09
US20200063174A1 (en) 2020-02-27
CN102822343B (zh) 2017-10-20
EP4130273A1 (en) 2023-02-08
AU2019206054B2 (en) 2022-03-10
AU2019206054A1 (en) 2019-08-08
AU2010343095A1 (en) 2012-08-09
IN2012DN06277A (show.php) 2015-09-25
JP2016047055A (ja) 2016-04-07
JP7585382B2 (ja) 2024-11-18
JP6339548B2 (ja) 2018-06-06
CA2785971C (en) 2019-02-12
JP2023101420A (ja) 2023-07-20
CA2785971A1 (en) 2011-07-28
WO2011090731A1 (en) 2011-07-28
JP2020096635A (ja) 2020-06-25
EP2519635B1 (en) 2018-11-21
EP2519635A1 (en) 2012-11-07
JP7745996B2 (ja) 2025-09-30
EP3505632A1 (en) 2019-07-03
EP4130273B1 (en) 2024-06-12
JP2013515503A (ja) 2013-05-09
CN107746869A (zh) 2018-03-02
AU2022203980B2 (en) 2024-12-12
AU2017202195B2 (en) 2019-04-18
JP5838496B2 (ja) 2016-01-06
US20110189228A1 (en) 2011-08-04
CA3028175A1 (en) 2011-07-28
EP2519635A4 (en) 2013-06-26
CA3153553A1 (en) 2011-07-28
US20150110826A1 (en) 2015-04-23
JP2025114812A (ja) 2025-08-05

Similar Documents

Publication Publication Date Title
CA3028175C (en) Methods of producing heterologous viral neuraminidase proteins in microalgae
JP5838473B2 (ja) 微細藻類におけるヘマグルチニン−ノイラミニダーゼタンパク質の産生方法
CA2755667C (en) Protein production in microorganisms of the phylum labyrinthulomycota
KR20210024625A (ko) 인플루엔자 바이러스 헤마글루티닌 돌연변이들
CN111315408A (zh) 在嗜热毁丝霉(myceliophthora thermophila)中生产流感疫苗
JP5838496B6 (ja) 微細藻類における異種ポリペプチド、微細藻類細胞外体、組成物の産生、ならびにそれらの作製および使用の方法
KR102568329B1 (ko) 조류인플루엔자 뉴라미니다아제를 포함하는 바이러스-유사입자 및 이를 이용한 범용 백신

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20181219

EEER Examination request

Effective date: 20181219